Castelli Jeff's most recent trade in Amicus Therapeutics Inc was a trade of 52,338 Common Stock done . Disclosure was reported to the exchange on Feb. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 52,338 | 488,200 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.57 per share. | 11 Feb 2025 | 22,724 | 465,476 (0%) | 0% | 9.6 | 217,469 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,517 | 150,517 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 83,073 | 453,288 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 14,299 | 438,989 (0%) | 0% | 9.4 | 134,554 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 6,990 | 370,215 (0%) | 0% | 9.3 | 65,077 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 3,127 | 435,862 (0%) | 0% | 9.4 | 29,425 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 14,405 | 387,210 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.65 per share. | 09 Jan 2024 | 10,005 | 362,800 (0%) | 0% | 13.6 | 136,568 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.65 per share. | 09 Jan 2024 | 10,005 | 377,205 (0%) | 0% | 13.6 | 136,568 | Common Stock |
| Amicus Therapeutics Inc | Castelli Jeff | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.44 per share. | 04 Jan 2024 | 3,127 | 372,805 (0%) | 0% | 13.4 | 42,027 | Common Stock |
| Amicus Therapeutics Inc | Castelli Jeff | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 99,073 | 99,073 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 57,392 | 398,053 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Castelli Jeff | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.53 per share. | 02 Jan 2024 | 14,083 | 375,932 (0%) | 0% | 13.5 | 190,543 | Common Stock |
| Amicus Therapeutics Inc | Castelli Jeff | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.24 per share. | 02 Jan 2024 | 8,038 | 390,015 (0%) | 0% | 14.2 | 114,461 | Common Stock |
| Amicus Therapeutics Inc | Castelli Jeff | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 14.52 per share. | 28 Dec 2023 | 17,421 | 340,661 (0%) | 0% | 14.5 | 252,902 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 13.25 per share. | 18 Dec 2023 | 17,500 | 359,736 (0%) | 0% | 13.3 | 231,875 | Common Stock |
| Amicus Therapeutics Inc | Castelli Jeff | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 8,643 | 377,236 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 13.10 per share. | 18 Dec 2023 | 1,654 | 358,082 (0%) | 0% | 13.1 | 21,667 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.77 per share. | 17 Aug 2023 | 14,560 | 368,593 (0%) | 0% | 12.8 | 185,931 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 56,024 | 407,478 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.02 per share. | 11 Jan 2023 | 24,325 | 383,153 (0%) | 0% | 12.0 | 292,387 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.03 per share. | 04 Jan 2023 | 3,127 | 351,454 (0%) | 0% | 12.0 | 37,618 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 125,462 | 125,462 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 70,681 | 360,992 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.21 per share. | 02 Jan 2023 | 13,944 | 290,311 (0%) | 0% | 12.2 | 170,256 | Common Stock |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.93 per share. | 02 Jan 2023 | 6,411 | 354,581 (0%) | 0% | 11.9 | 76,483 | Common Stock |